IntelGenx (TSXV:IGX; OTCQB:IGXT) signed a binding letter of intent (LOI) with Heritage Cannabis (CSE:CANN; OTCQX:HERTF) for the supply of CBD-containing filmstrip products for the Canadian and Australian markets. Under...
FiercePharma featured IntelGenx (TSXV:IGX; OTCQX:IGXT) and its two recent deals for the development of psychedelic oral films. In July and August, the company signed feasibility agreements with Cybin Corp. and ATAI Life...
IntelGenx (TSXV:IGX; OTCQB:IGXT) granted its partner, Exeltis Healthcare, an exclusive license to manufacture and commercialize RIZAPORT in the EU. Under the accord, Exeltis will pay IntelGenx royalties on net RIZAPORT...
IntelGenx (TSXV:IGX; OTCQB:IGXT) and ATAI Life Sciences signed a feasibility agreement for the development of novel formulations of pharmaceutical-grade psychedelics, based on IntelGenx’s film technologies. Under...
IntelGenx (TSXV:IGX; OTCQB:IGXT) and Tilray (NASDAQ:TLRY) amended the exclusivity terms of their November 2018 license, development and supply agreement to allow for IntelGenx’s co-development and commercialization of...
IntelGenx (TSXV:IGX; OTCQB:IGXT) inked a feasibility agreement with Cybin for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin. Cybin is Canada’s premier mushroom...
Health Canada has cleared IntelGenx (TSXV:IGX; OTCQB:IGXT) to begin selling its liquid and gel hand sanitizer formulations, which will be produced using excess capacity at the company’s cGMP manufacturing facility in...
IntelGenx (TSXV:IGX; OTCQB:IGXT) received a cannabis micro-processing license from Health Canada under the Cannabis Act and Cannabis Regulations for the company’s Montreal, Quebec facility. “Receipt of this cannabis...
The FDA has granted IntelGenx Technologies’ (TSXV:IGX; OTCQX:IGXT) request for a Type A meeting to discuss the company’s RIZAPORT VersaFilm program. The meeting is scheduled for June 10, 2020. On March...